# Post Marketing Surveillance (PMS) Study of Cresemba in Korea.

> **NCT04744454** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 94 (actual)

## Conditions studied

- Aspergillosis
- Mucormycosis

## Interventions

- **DRUG:** Isauvuconazole group

## Key facts

- **NCT ID:** NCT04744454
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-28
- **Primary completion:** 2026-01-13
- **Final completion:** 2026-01-13
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04744454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04744454, "Post Marketing Surveillance (PMS) Study of Cresemba in Korea.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04744454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*